Show simple item record

dc.contributor.authorFerraldeschi, Roberta
dc.contributor.authorThatcher, Nick
dc.contributor.authorLorigan, Paul C
dc.date.accessioned2009-07-07T15:06:39Z
dc.date.available2009-07-07T15:06:39Z
dc.date.issued2007-05
dc.identifier.citationPemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial. 2007, 7 (5):635-40 Expert Rev Anticancer Theren
dc.identifier.issn1744-8328
dc.identifier.pmid17492928
dc.identifier.doi10.1586/14737140.7.5.635
dc.identifier.urihttp://hdl.handle.net/10541/72787
dc.description.abstractPemetrexed is a novel, multitargeted antifolate currently under development for the treatment of a number of solid tumors, including small-cell lung cancer. Pemetrexed/platinum combinations appear to compare favorably with other platinum-based doublets in terms of their efficacy and safety profile. The Global Analysis of Pemetrexed in SCLC Extensive Stage (GALES) trial is a direct comparison of pemetrexed and carboplatin with the standard first-line etoposide and carboplatin chemotherapy in extensive-disease small-cell lung cancer. This randomized, multicenter, open-label Phase III study will enroll 1820 patients in 23 countries, with the final analysis planned after 1270 deaths have occurred. An interim analysis will be conducted after 700 patients have been enrolled. The study will also use pharmacogenomic analysis to evaluate biological predictors of response, in particular to pemetrexed.
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarboplatin
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshCarcinoma, Small Cell
dc.subject.meshEtoposide
dc.subject.meshGlutamates
dc.subject.meshGuanine
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMesothelioma
dc.subject.meshRandomized Controlled Trials as Topic
dc.titlePemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. roberta_ferraldeschi@yahoo.comen
dc.identifier.journalExpert Review of Anticancer Therapyen
html.description.abstractPemetrexed is a novel, multitargeted antifolate currently under development for the treatment of a number of solid tumors, including small-cell lung cancer. Pemetrexed/platinum combinations appear to compare favorably with other platinum-based doublets in terms of their efficacy and safety profile. The Global Analysis of Pemetrexed in SCLC Extensive Stage (GALES) trial is a direct comparison of pemetrexed and carboplatin with the standard first-line etoposide and carboplatin chemotherapy in extensive-disease small-cell lung cancer. This randomized, multicenter, open-label Phase III study will enroll 1820 patients in 23 countries, with the final analysis planned after 1270 deaths have occurred. An interim analysis will be conducted after 700 patients have been enrolled. The study will also use pharmacogenomic analysis to evaluate biological predictors of response, in particular to pemetrexed.


This item appears in the following Collection(s)

Show simple item record